发明名称 |
Responsiveness to angiogenesis inhibitors |
摘要 |
Disclosed is an in vitro method of determining whether a patient is suitably treated by a therapy comprising an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as bevacizumab, said method comprising: (a) determining in a sample derived from a patient suffering from cancer the genotype at polymorphism rs12505758 (SEQ ID NO. 2), and (b) identifying a patient as more or less suitably treated by a therapy with an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as bevacizumab based on said genotype, wherein the presence of each T allele at polymorphism rs12505758 (SEQ ID NO. 2) indicates an increased likelihood that said patient is more suitably treated, or the presence of each C allele at polymorphism rs12505758 (SEQ ID NO. 2) indicates an increased likelihood that said patient is less suitably treated. |
申请公布号 |
NZ620345(A) |
申请公布日期 |
2016.06.24 |
申请号 |
NZ20120620345 |
申请日期 |
2012.08.28 |
申请人 |
F. HOFFMANN-LA ROCHE AG;LIFE SCIENCES RESEARCH PARTNERS VZW;VIB VZW |
发明人 |
DELMAR PAUL;DE HAAS SANNE LYSBET;SCHERER STEFAN;LAMBRECHTS DIETHER |
分类号 |
C12Q1/68;A61K39/395;A61K45/06 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|